DRIODarioHealth Corp.

Net loss improved 39% amid shift to higher-margin B2B2C revenue.

DarioHealth Corp (DRIO) reports improved gross margins and reduced losses while navigating a revenue dip from pharma exit and implementation timing.

Moby summary of DarioHealth Corp.'s Q2 2026 earnings call

DarioHealth (NASDAQ:DRIO) reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the first quarter and $5.4 million a year earlier, as the company continued to shift away from pharmaceutical services revenue toward recurring B2B2C business. Chief Financial Officer Chen Fran

DarioHealth (DRIO) delivered earnings and revenue surprises of +25.00% and -16.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

(Bloomberg) -- CoreWeave Inc. shares have been on a roll lately after a monthslong slump. Now, the neocloud provider’s earnings after the close Tuesday can give investors a sense of whether the rally is sustainable. Most Read from BloombergChina Unleashes $28 Trillion Capital Markets to Challenge US in AINvidia Taps Wall Street for $500 Billion Funding CommitmentTrump Makes Sweeping New Demands on Iran as Deal Hopes DimStocks Churn as Hormuz Standoff Spurs Rally in Oil: Markets WrapIran Shakes U

The Joint (JYNT) delivered earnings and revenue surprises of -109.09% and +3.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DarioHealth (DRIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/or hypertension. The program will be available to more than 100,000 eligible employees and is expected to launch in Fall 2026. "Winning another Fortune 50 employer underscores the growing recognition that integrated chronic condition management delivers better outcomes than treating each condition independently, resulting in clinically significant outcomes and economic impact," said Erez Raphael, Chief Executive Officer of Dario.